Milrinone - Revision history

Danbot: Switch SMW query from broadtable to table format for better layout with TOC

2026-03-20T21:56:49Z

Switch SMW query from broadtable to table format for better layout with TOC

← Older revision		Revision as of 21:56, 20 March 2026
Line 82:		Line 82:
	\|?Has Route=Route		\|?Has Route=Route
	\|?Has Population=Population		\|?Has Population=Population
	\|format=~~broadtable~~		\|format=table
	\|headers=plain		\|headers=plain
	\|mainlabel=-		\|mainlabel=-

Danbot: Fix SMW query: replace link=subject with mainlabel=- to fix broken subobject fragment links

2026-03-20T17:26:33Z

Fix SMW query: replace link=subject with mainlabel=- to fix broken subobject fragment links

← Older revision		Revision as of 17:26, 20 March 2026
Line 84:		Line 84:
	\|format=broadtable		\|format=broadtable
	\|headers=plain		\|headers=plain
	\|~~link~~=~~subject~~		\|mainlabel=-
	\|sort=Has Indication		\|sort=Has Indication
	\|limit=50		\|limit=50

Danbot: Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template)

2026-03-20T16:44:43Z

Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template)

@@ Line 71: / Line 71: @@
 ===Indication===
 *low cardiac output states due to impaired myocardial contractility
 ==See Also==

Ostermayer at 16:01, 25 July 2025

2025-07-25T16:01:57Z

← Older revision		Revision as of 16:01, 25 July 2025
Line 1:		Line 1:
	==General==		==General==
	*Type: [[Vasopressors]]		*Type: [[Is DrugClass::Vasopressors]]
	*Dosage Forms: INJ		*Dosage Forms: INJ
	*Common Trade Names: Milrinone		*Common Trade Names: Milrinone

ClaireLewis: /* References */

2019-09-22T23:28:51Z

References

← Older revision		Revision as of 23:28, 22 September 2019
Line 79:		Line 79:

	[[Category:Pharmacology]]		[[Category:Pharmacology]]
			[[Category:Cardiology]]

ELEE1987: /* Pharmacology */

2017-10-24T17:35:04Z

Pharmacology

← Older revision		Revision as of 17:35, 24 October 2017
Line 55:		Line 55:
	*Metabolism: Glucouronidation		*Metabolism: Glucouronidation
	*Excretion: Urine primarily		*Excretion: Urine primarily
	*Mechanism of Action:		*Mechanism of Action: inhibits cAMP phosphodiesterase
	===Primary Receptor===		===Primary Receptor===
	*PDE-3 inhibitor		*PDE-3 inhibitor
Line 61:		Line 61:
	*↑HR		*↑HR
	*↑↑↑SV		*↑↑↑SV
	*↓SVR		*↓SVR

	==Notes==		==Notes==

Jonwarren: Added renal dosing and pharmacology

2017-08-10T16:28:25Z

Added renal dosing and pharmacology

← Older revision		Revision as of 16:28, 10 August 2017
Line 1:		Line 1:
	==General==		==General==
	*Type: [[Vasopressors]]		*Type: [[Vasopressors]]
	*Dosage Forms:		*Dosage Forms: INJ
	*Common Trade Names:		*Common Trade Names: Milrinone

	==Adult Dosing==		==Adult Dosing==
Line 15:		Line 15:

	==Special Populations==		==Special Populations==
	*[[Drug Ratings in Pregnancy\|Pregnancy Rating]]:		*[[Drug Ratings in Pregnancy\|Pregnancy Rating]]: C; Caution advised
	*Lactation:		*Lactation: Safety unknown
	*Renal Dosing		*Renal Dosing
	**Adult		**Adult
			***CrCl 50: Start 0.43 mcg/kg/min
			***CrCl 40: Start 0.38 mcg/kg/min
			***CrCl 30: Start 0.33 mcg/kg/min
			***CrCl 20: Start 0.28 mcg/kg/min
			***CrCl 10: Start 0.23 mcg/kg/min
			***CrCl 5: Start 0.20 mcg/kg/min
	**Pediatric		**Pediatric
			***CrCl 50: Start 0.43 mcg/kg/min
			***CrCl 40: Start 0.38 mcg/kg/min
			***CrCl 30: Start 0.33 mcg/kg/min
			***CrCl 20: Start 0.28 mcg/kg/min
			***CrCl 10: Start 0.23 mcg/kg/min
			***CrCl 5: Start 0.20 mcg/kg/min
	*Hepatic Dosing		*Hepatic Dosing
	**Adult		**Adult
			***Not defined
	**Pediatric		**Pediatric
			***Not defined

	==Contraindications==		==Contraindications==
	*Allergy to class/drug		*Allergy to class/drug
			*Aortic valve disease, severe
			*Pulmonic valve disease, severe
			*[[MI]], acute

	==Adverse Reactions==		==Adverse Reactions==
	*Tachyarrhythmias		*Tachyarrhythmias
	*Hypotension		*[[Hypotension]]
	*~~Myocardial ischemia~~		*[[Torsades de pointes]]
			*[[Anaphylaxis]]
			*Bronchospasm

	==Pharmacology==		==Pharmacology==
	*Half-life:		*Half-life: 2.3h
	*Metabolism:		*Metabolism: Glucouronidation
	*Excretion:		*Excretion: Urine primarily
	*Mechanism of Action:		*Mechanism of Action:
	===Primary Receptor===		===Primary Receptor===

Mholtz at 06:48, 13 July 2017

2017-07-13T06:48:04Z

← Older revision		Revision as of 06:48, 13 July 2017
Line 51:		Line 51:

	===Indication===		===Indication===
	low cardiac output states due to impaired myocardial contractility		*low cardiac output states due to impaired myocardial contractility

	==See Also==		==See Also==


	==References==		==References==
			<references/>

	~~<references/>~~
	[[Category:Pharmacology]]		[[Category:Pharmacology]]

Neil.m.young: Text replacement - " pt " to " patient "

2016-07-01T22:01:08Z

Text replacement - " pt " to " patient "

← Older revision		Revision as of 22:01, 1 July 2016
Line 48:		Line 48:
	*Causes pulmonary vasodilation, may be good choice in patients with RV failure		*Causes pulmonary vasodilation, may be good choice in patients with RV failure
	*↑cAMP in cardiac myocytes and vascular smooth muscle, thereby ↑HR and ↑SV while decreasing ↓SVR		*↑cAMP in cardiac myocytes and vascular smooth muscle, thereby ↑HR and ↑SV while decreasing ↓SVR
	*Use with caution in pt with renal failure and hypovolemia		*Use with caution in patient with renal failure and hypovolemia

	===Indication===		===Indication===

Neil.m.young: Text replacement - "==Sources==" to "==References=="

2016-06-26T23:01:22Z

Text replacement - "==Sources==" to "==References=="

← Older revision		Revision as of 23:01, 26 June 2016
Line 55:		Line 55:
	==See Also==		==See Also==

	==~~Sources~~==		==References==

	<references/>		<references/>
	[[Category:Pharmacology]]		[[Category:Pharmacology]]